Full-Time

Associate Medical Coding Director

Biotechnology Oncology

Posted on 4/29/2025

Exelixis

Exelixis

1,001-5,000 employees

Develops and commercializes cancer therapies

Compensation Overview

$141k - $199.5k/yr

+ Bonus + Sales-based Incentive Plan

Expert

King of Prussia, PA, USA + 1 more

More locations: Alameda, CA, USA

Category
Public Health
Diagnostics & Laboratory Professionals
Medical, Clinical & Veterinary
Biology & Biotech
Requirements
  • BS/BA degree with related health science background (e.g. Nursing, Pharmacy) and a minimum of 11 years of related experience; or,
  • MS/MA degree with related health science background (e.g. Nursing, Pharmacy) and a minimum of 9 years of related experience; or,
  • PhD in related discipline and a minimum of 5 years of related experience, or;
  • Equivalent combination of education and experience.
  • May require certification in assigned area.
  • 10+ years of related experience and/or combination of experience and education/training.
  • 10+ years of pharmaceutical/biotechnology/CRO in Medical Dictionary Coding, Clinical Data Management and project management.
  • Advanced knowledge of ICH-GCP guidelines and applicable drug development regulations.
  • Strong understanding of drug development and clinical trial execution, including other required functional areas involved in clinical trials.
  • Must have a strong understanding and utilization of medical terminology.
  • Experience in coding medical data (adverse events and concomitant medications) and understanding of the clinical coding process is required. Working knowledge of MedDRA, and WHODrug is strongly required.
  • Experience with Clinical trial data systems and/or EDC coding tools is required with Medidata Coder experience preferred.
Responsibilities
  • Provides and enables solutions for complex problem solving that align with the Exelixis values.
  • Establishes Program(s) or Portfolio level dictionary coding strategies and is accountable for the management of vendor partnerships to maximize effectiveness and maintain budgets.
  • Leads clinical trial coding deliverables and activities that support Exelixis regulatory commitments including submission of safety data.
  • Provides coding expertise and capability in support of global development programs.
  • Serves as a medical coding subject matter expert within Exelixis.
  • Partners with stakeholders including CDM Systems and Digital Transformation to optimize technology that supports efficient dictionary management processes and with Global Patient Safety and Clinical Development for oversight of vendor coding quality.
  • Develops and maintains Exelixis coding conventions to ensure consistency across studies and programs.
  • Reviews program and study-level clinical trials, serious adverse events (SAE), concomitant medications, and other relevant coded data performed by vendors for quality and consistency.
Desired Qualifications
  • Ability to prioritize and multi-task successfully in a fast-paced and changing environment.
  • Excellent interpersonal and communication skills, both written and oral, including ability to develop strong relationships with internal and external stakeholders.
  • Excellent organizational skills with strong attention to detail; proven ability to handle multiple tasks efficiently, effectively, and timely.
  • Demonstrated ability to think strategically across the organization.
  • Self-motivated, calm under pressure and adaptable to a dynamic environment with the ability to support successful change.
  • Must be detail-oriented with the ability to handle multiple projects and priorities.
  • Demonstrates effective interpersonal and communication skills.
  • Ability to contribute to the definition and timely achievement of area projects and goals and serve as a representative for Coding on cross functional projects.
  • Problem solving skills should involve identification of problems and proper escalation.
  • Must be able to work independently as well as in a team environment and effectively collaborate with stakeholders for effective outcomes.

Exelixis develops and commercializes medicines specifically for cancer treatment. The company creates therapies that target various biological pathways and can be used in combination with other treatments, aiming to offer effective and manageable options for patients. Exelixis primarily focuses on advanced cancers, such as renal cell carcinoma, and engages in extensive research, clinical trials, and obtaining regulatory approvals to introduce new drugs to the market. Unlike many competitors, Exelixis emphasizes combination therapies to enhance treatment effectiveness. The goal of Exelixis is to improve patient outcomes and provide hope for remission through its drug development efforts.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

San Francisco, California

Founded

1994

Simplify Jobs

Simplify's Take

What believers are saying

  • Strategic partnerships can expand Exelixis' pipeline and market reach.
  • AI-driven drug discovery accelerates identification of novel cancer targets for Exelixis.
  • Telemedicine improves patient monitoring, enhancing outcomes of Exelixis' therapies.

What critics are saying

  • Generic competition may reduce market share for CABOMETYX®.
  • Reliance on future drug approvals may not meet expectations.
  • Need for additional funding may indicate financial pressures.

What makes Exelixis unique

  • Exelixis focuses on combination regimens for advanced cancer treatment.
  • The company targets multiple pathways to create effective and durable cancer therapies.
  • Exelixis has a strong pipeline with four molecules in preclinical stages.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Performance Bonus

Employee Stock Purchase Plan

Company News

Medical Update Online
Mar 28th, 2025
Exelixis to present preclinical data for four pipeline molecules at AACR 2025

Exelixis to present preclinical data for four pipeline molecules at AACR 2025.

Defense World
Mar 9th, 2025
Proficio Capital Partners LLC Makes New Investment in Exelixis, Inc. (NASDAQ:EXEL)

Proficio Capital Partners LLC makes new investment in Exelixis, Inc. (NASDAQ:EXEL).

Stock Titan
Feb 13th, 2025
Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit

Exelixis to participate in the Citi 2025 Virtual Oncology Leadership Summit.

MarketBeat
Jan 7th, 2025
Range Financial Group LLC Invests $994,000 in Exelixis, Inc. (NASDAQ:EXEL)

Range Financial Group LLC invests $994,000 in Exelixis, Inc. (NASDAQ:EXEL).

Stock Titan
Jan 6th, 2025
Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025

Exelixis to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025.